Mercy BioAnalytics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mercy BioAnalytics, Inc. - overview
Established
2018
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2018 by Joseph Sedlak, and Paul Blavin, Mercy BioAnalytics, Inc. operates as a biotech company dedicated to the early detection of cancer through the use of extracellular vesicles (EVs) found in the blood. In September 2025, Mercy BioAnalytics, Inc. raised USD 59 million in series B funding co-led by returning investor Novalis LifeSciences and Sozo Ventures, with participation from new investors Hologic, Perceptive Advisors, Portfolia, Avestria Ventures, and Mindshift Capital.
Other returning investors BrightEdge Ventures, iSelect Fund Management, Bruker Corporation, and LabCorp Ventures also participated in the round. Mercy BioAnalytics, Inc. developed a blood-based assay called the Halo test, for the early detection of various types of cancer, including ovarian and lung cancer. It analyzes single extracellular vesicles (EVs) and utilizes the surface proteins that carry information about their tumor cell of origin to achieve sensitivity and specificity.
The platform utilizes biomarker co-localization to interrogate highly abundant, blood-based extracellular vesicles. The abundance of extracellular vesicles in circulation enables the Mercy Halo test to be run on a very small volume of serum or plasma with a PCR-based read-out. The company will use the September 2025 funding for the expansion of its Mercy Halo portfolio.
Current Investors
Hatteras Venture Partners, Bruker Corporation, Sozo Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.mercybio.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.